Phospho-JAK1 (Tyr1034/Tyr1035) Antibody

WB
Cites

1/2

Phospho-JAK1 (Tyr1034/Tyr1035) Antibody - Western blot analysis of extracts from A549 cells, using Phospho-JAK1 (Tyr1034/Tyr1035) Antibody.

Phospho-JAK1 (Tyr1034/Tyr1035) Antibody - FIGURE 2 Immunochemistry for CD8, CXCL10 and CXCR3 in mice skins and Western blotting analysis of JAK/STAT pathway in HaCaT.

Product:	Phospho-JAK1 (Tyr1034/Tyr1035) Antibody
Catalog:	AF3701
Description:	Rabbit polyclonal antibody to Phospho-JAK1 (Tyr1034/Tyr1035)
Application:	WB
Cited expt.:	WB
Reactivity:	Human, Mouse, Rat
Mol.Wt.:	133kD(Calculated).
Uniprot:	P23458
RRID:	AB_2847015

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
100ul	$350	In stock
200ul	$450	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500-1:2000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human,Mouse,Rat

Clonality:

Polyclonal

Specificity:

Phospho-JAK1 (Tyr1034/Tyr1035) Antibody detects endogenous levels of JAK1 only when phosphorylated at Tyr1034/Tyr1035.

RRID:

AB_2847015
Cite Format: Affinity Biosciences Cat# AF3701, RRID:AB_2847015.

Conjugate:

Unconjugated.

Purification:

The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.

Storage:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

JAK 1; JAK 1A; JAK 1B; JAK-1; JAK1; JAK1_HUMAN; JAK1A; JAK1B; Janus kinase 1 (a protein tyrosine kinase); Janus kinase 1; JTK3; Tyrosine protein kinase JAK 1; Tyrosine protein kinase JAK1; Tyrosine-protein kinase JAK1;

Immunogens

Immunogen:

A synthesized peptide derived from human JAK1 around the phosphorylation site of Tyr1034/Tyr1035.

Uniprot:

P23458(JAK1_HUMAN) >>Visit HPA database.

Gene(ID):

JAK1(3716)

Expression:

P23458 JAK1_HUMAN:

Expressed at higher levels in primary colon tumors than in normal colon tissue. The expression level in metastatic colon tumors is comparable to the expression level in normal colon tissue.

Sequence:

P23458 JAK1_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MQYLNIKEDCNAMAFCAKMRSSKKTEVNLEAPEPGVEVIFYLSDREPLRLGSGEYTAEELCIRAAQACRISPLCHNLFALYDENTKLWYAPNRTITVDDKMSLRLHYRMRFYFTNWHGTNDNEQSVWRHSPKKQKNGYEKKKIPDATPLLDASSLEYLFAQGQYDLVKCLAPIRDPKTEQDGHDIENECLGMAVLAISHYAMMKKMQLPELPKDISYKRYIPETLNKSIRQRNLLTRMRINNVFKDFLKEFNNKTICDSSVSTHDLKVKYLATLETLTKHYGAEIFETSMLLISSENEMNWFHSNDGGNVLYYEVMVTGNLGIQWRHKPNVVSVEKEKNKLKRKKLENKHKKDEEKNKIREEWNNFSYFPEITHIVIKESVVSINKQDNKKMELKLSSHEEALSFVSLVDGYFRLTADAHHYLCTDVAPPLIVHNIQNGCHGPICTEYAINKLRQEGSEEGMYVLRWSCTDFDNILMTVTCFEKSEQVQGAQKQFKNFQIEVQKGRYSLHGSDRSFPSLGDLMSHLKKQILRTDNISFMLKRCCQPKPREISNLLVATKKAQEWQPVYPMSQLSFDRILKKDLVQGEHLGRGTRTHIYSGTLMDYKDDEGTSEEKKIKVILKVLDPSHRDISLAFFEAASMMRQVSHKHIVYLYGVCVRDVENIMVEEFVEGGPLDLFMHRKSDVLTTPWKFKVAKQLASALSYLEDKDLVHGNVCTKNLLLAREGIDSECGPFIKLSDPGIPITVLSRQECIERIPWIAPECVEDSKNLSVAADKWSFGTTLWEICYNGEIPLKDKTLIEKERFYESRCRPVTPSCKELADLMTRCMNYDPNQRPFFRAIMRDINKLEEQNPDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK

Research Backgrounds

P23458_JAK1_HUMAN

Function:

Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor as well as interleukin (IL)-10 receptor.

PTMs:

Autophosphorylated. Phosphorylated on tyrosine residues in response to interferon gamma signaling. Dephosphorylation of Tyr-1034 and Tyr-1035 by PTPN2 negatively regulates cytokine-mediated signaling.

Ubiquitinated by RNF125; leading to its degradation by the proteasome.

Subcellular Location:

Endomembrane system>Peripheral membrane protein.
Note: Wholly intracellular, possibly membrane associated.

Tissue Specificity:

Expressed at higher levels in primary colon tumors than in normal colon tissue. The expression level in metastatic colon tumors is comparable to the expression level in normal colon tissue.

Family&Domains:

Possesses two phosphotransferase domains. The second one probably contains the catalytic domain, while the presence of slight differences suggest a different role for domain 1.

The FERM domain mediates interaction with JAKMIP1.

Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.

Research Fields

· Cellular Processes > Cell growth and death > Necroptosis. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells. (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway. (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Specific types > Pancreatic cancer. (View pathway)

· Organismal Systems > Development > Osteoclast differentiation. (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Th1 and Th2 cell differentiation. (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation. (View pathway)

References

1). DCUN1D1, a new molecule involved in depigmentation via upregulating CXCL10. Experimental dermatology, 2023 (PubMed: 36541112) [IF=3.5]

Application: WB Species: Mouse Sample:

FIGURE 2 Immunochemistry for CD8, CXCL10 and CXCR3 in mice skins and Western blotting analysis of JAK/STAT pathway in HaCaT. (A) Detection of CD8, CXCL10 and CXCR3 through immunohistochemistry. Strong staining of CD8 was observed in the AAV-KRT14-Dcun1d1 group, but expression of CD8 was mild in the control and negative control groups. Compared with the other groups, CXCL10 staining was observed in dermal parts of skin biopsy sections from the AAV-KRT14-Dcun1d1 group. CXCR3 staining was close to the portal regions or blood vessels. The expression of CXCR3 was upregulated in the control and negative control groups. Red arrows indicate positive staining. A section of the image (magnification, ×100) in the upper column marked with the brown dotted frame is enlarged and displayed in the lower column. (B), Inhibition of DCUN1D1 by sgRNA was assessed by western blotting. (C), Expression levels of P-JAK1, P-JAK2, P-STAT1 and CXCL10 were assessed by Western blotting. (D–G), Statistical analysis. ns means no significant difference.

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

Phospho-JAK1 (Tyr1034/Tyr1035) Antibody - #AF3701